Inspections, Compliance, Enforcement, and Criminal Investigations
Thai Kee Trading Company 22-Jan-04
Department of Health and Human Services
Public Health Service
San Francisco District
VIA FEDERAL EXPRESS
January 22, 2004
Our Reference: FEI 1000161889
Lawrence T. Huang, Chief Executive Officer
Thai Kee Trading Company
660 N. King Road
San Jose, California 95133
Dear Mr. Huang:
We inspected your seafood firm on October 10, 21, and 22, 2003. We conducted this inspection to determine your compliance with FDA's seafood processing regulations, Title 21, Code of Federal Regulations, Part 123.
We found that your firm has a serious HACCP deviation. This deviation causes your Fish Sauce to be adulterated within the meaning of Section 402(a)(4) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 342(a)(4), in that the Fish Sauce has been prepared, packed, or held under insanitary conditions, whereby it may have been rendered injurious to health. We listed the HACCP deviation on a Form FDA 483 and discussed them with you, at the conclusion of the inspection. Your serious HACCP deviation was:
You must have product specifications that are designed to ensure that fish and fishery products you import are not injurious to health, to comply with 21 CFR 123.12(a)(2)(i). However, your firm does not have a product specification for Fish Sauce imported from [redacted]
The above-identified deviation is not intended to be an all inclusive list of deficiencies at your facility. It is your responsibility to ensure that all seafood products processed and distributed by your firm are in compliance with the Act and all requirements of the federal regulations.
You should take prompt measures to correct this deviation. Failure to promptly correct the deviation noted may result in regulatory action without further notice. Such action includes seizure and/or injunction. In addition, FDA may detain your imported seafood products without examination.
Please respond in writing within fifteen (15) working days of receipt of this letter. Your response should outline the specific steps you have taken to correct the violation, including an explanation of each step taken to prevent their recurrence. Your response should include copies of any available documentation demonstrating that corrections have been made. If you cannot complete all the corrections before you respond, we expect that you will explain the reason for your delay and state when you will correct any remaining deficiencies.
Please send your reply to the Food and Drug Administration, Attention: Erlinda N. Figueroa, Compliance Officer, 1431 Harbor Bay Parkway, Alameda, California 94502-7070. If you have questions regarding any issue in this letter, please contact Ms. Figueroa at (510) 337-3795.
Elizabeth A. Keville
Acting District Director
San Francisco District